Weice biological IPO meeting: annual revenue of 1.26 billion Ruihong investment and Yaohe medicine are shareholders

RedI network Lei Jianping 7 month 25 Reported Wednesday

Hangzhou Weice Biotechnology Co., Ltd （ abbreviation ：“ Micro strategy creatures ”） recently IPO Past meeting , It is expected that the registration will be submitted in the next step , Prepare to be listed on the growth enterprise market of Shenzhen Stock Exchange .

Wechat biological plan fundraising 7.75 One hundred million yuan , among ,2.8 Billion yuan for annual output 10 Blood glucose test paper for 100 million people ,300 Ten thousand blood glucose meters project ,2.43 100 million yuan per year 50 Ten thousand testing instruments and 2 Production project of 100 million test reagents ,1.82 100 million yuan for R & D center construction projects ,7012.6 Ten thousand yuan is used for the upgrading project of marketing and service network system .

Annual revenue 12.63 Billion

Weice biology is a high-tech enterprise located in Linping District, Hangzhou . since 2013 year 8 Since its establishment in , Specialized in POCT Product development 、 Production and sales .

The products of weice biology have been exported to the United States 、 Italy 、 Germany 、 Turkey, etc 100 Multiple countries and regions , Widely recognized by local customers , And in the United States 、 Hong Kong and India have set up overseas subsidiaries . In the Chinese market , Wechat biological products are sold in the near future 400 Second level and above hospitals .

The prospectus shows , Micro strategy creatures 2019 year 、2020 year 、2021 The annual revenue is 1.69 One hundred million yuan 、6.72 One hundred million yuan 、12.63 One hundred million yuan ; The net profit is respectively 1392.4 Ten thousand yuan 、1.6 One hundred million yuan 、3.28 One hundred million yuan ; The net profit after deducting non profits is 724.9 Ten thousand yuan 、1.71 One hundred million yuan 、3.13 One hundred million yuan .

Ruihong investment and Yaohe medicine are shareholders

Rong Yang 、 Yang Qinggang and Wang Chengchao are the joint actual controllers of the company , Both have served as directors and important management positions in the company .

among , Rong Yang 、 Yang Qinggang 、 Wang Chengchao passed Hangzhou Weibo 、 Wechat health indirect control company 33.26% equity , Yang Rong passed Hangzhou Zhide 、 Hurong investment indirect control company 3.06% equity , Yang Qinggang made another investment through Heshi 、 Heyu management indirect control company 4.94% equity , Wang Chengchao indirectly controls the company through Heguo investment 8.88% equity , Three people together can control the company 50.14% equity .

Ms. Yang Rong ,1975 year 7 born ,2000 Graduated from Zhejiang University, majoring in genetics .2000 year 6 Month to 2012 year 7 month , Working in Aikang Biotechnology （ Hangzhou ） Co., LTD. , Successively served as R & D director 、 Director of research and development 、 Executive director and deputy general manager ;2012 year 8 Month to 2014 year 1 month , Take care of your children at home ;2014 year 2 Monthly entry into the company , Deputy general manager ;2015 year 12 Month to 2016 year 9 month , Serve as the director and deputy general manager of the company ;2016 year 9 Month so far , Served as the chairman and deputy general manager of the company .

Yang Qinggang ,1979 year 1 born ,1999 Graduated from the Department of biological science and technology of Zhejiang University .1999 year 9 Month to 2001 year 4 month , Worked in Zhejiang Wanma Pharmaceutical Co., Ltd , As a technician ;2001 year 4 Month to 2009 year 11 month , Working in Aikang Biotechnology （ Hangzhou ） Co., LTD. , Successively served as technician 、 R & D director and R & D Manager ;2009 year 11 Month to 2013 year 8 month , Worked in Hangzhou Wangying Technology Co., Ltd , Quality Manager ;2013 year 8 Month to 2016 year 9 month , Chairman and general manager of the company ;2016 year 9 Month so far , As director and general manager ;2021 year 11 Month so far , Serve as the director of the public health center .

Wangchengchao ,1982 year 1 born , Bachelor degree ,2003 Graduated from Nanjing University of technology, majoring in bioengineering .2004 year 3 Month to 2012 year 4 month , Working in Aikang Biotechnology （ Hangzhou ） Co., LTD. , Successively served as product management specialist 、 International sales representative 、 Director of international sales and director of international sales ;2012 year 5 Month to 2012 year 10 month , unemployed ;2012 year 11 Month to 2014 year 1 month , Worked in Nanjing plosheng Biomedical Technology Co., Ltd （ Its main business is cell biology technology and Application ）, Serve as commercial director ;2014 year 1 Month so far , Serve as the deputy general manager of the company ;2016 So far this year , Serve as the director and deputy general manager of the company .

Yang Rong's spouse is Zhao Wenyu , The actual controller Yang Qinggang's spouse is Tang Lina , The spouse of the actual controller Wang Chengchao is Zhang Haiyan .

IPO front , Hangzhou Weizhu holds 31.33%, Ruihong investment holding is 14.57%, Yaohe pharmaceutical holds 12.66%, Heguo investment holds 8.88%, Dongfang Yirui holds 7.91%; Ma Bilie holds 6.12%, The shareholding of Heyu management is 3.52%, Ma Shuang 、 Lang Taosha investment holds 3.08%, Hangzhou Zhide holds 2.26%, Wechat health holdings is 1.93%, The shareholding of Heshi investment is 1.42%.

IPO after , Hangzhou Weizhu holds 23.5%, Ruihong investment holding is 10.92%, Yaohe pharmaceutical holds 9.5%, Heguo investment holds 6.66%, Dongfang Yirui holds 5.94%;

Ma Bilie holds 4.59%, The shareholding of Heyu management is 2.64%, Ma Shuang 、 Lang Taosha investment holds 2.31%, Hangzhou Zhide holds 1.7%, Wechat health holdings is 1.45%.

———————————————

Lei Di was founded by Lei Jianping, a senior media person , If reproduced, please indicate the source .